MABCURE INC. INVESTMENT AGREEMENTInvestment Agreement • January 20th, 2011 • Mabcure Inc. • In vitro & in vivo diagnostic substances • Georgia
THIS INVESTMENT AGREEMENT DOES NOT CONSTITUTE AN OFFER TO SELL, OR A SOLICITATION OF AN OFFER TO PURCHASE, ANY OF THE SECURITIES DESCRIBED HEREIN BY OR TO ANY PERSON IN ANY JURISDICTION IN WHICH SUCH OFFER OR SOLICITATION WOULD BE UNLAWFUL. THESE SECURITIES HAVE NOT BEEN RECOMMENDED BY ANY FEDERAL OR STATE SECURITIES AUTHORITIES, NOR HAVE SUCH AUTHORITIES CONFIRMED THE ACCURACY OR DETERMINED THE ADEQUACY OF THIS DOCUMENT. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • January 20th, 2011 • Mabcure Inc. • In vitro & in vivo diagnostic substances • Georgia
This Registration Rights Agreement (this "Agreement"), dated as of January 18, 2011, by and between MabCure, Inc., a Nevada corporation (the "Company"), and Centurion Private Equity, LLC, a limited liability company organized under the laws of the state of Arizona (”Investor” or the “Holder”).
ContractPrivate Placement Subscription Agreement • March 8th, 2007 • Smartec Holdings Inc. • Nevada
THIS PRIVATE PLACEMENT SUBSCRIPTION AGREEMENT (THE "SUBSCRIPTION AGREEMENT") RELATES TO AN OFFERING OF SECURITIES IN AN OFFSHORE TRANSACTION TO PERSONS WHO ARE NOT U.S. PERSONS (AS DEFINED HEREIN) PURSUANT TO REGULATION S UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "1933 ACT").
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • January 20th, 2011 • Mabcure Inc. • In vitro & in vivo diagnostic substances • Georgia
SECURITIES PURCHASE AGREEMENT (this "Agreement," “Purchase Agreement,” or “Securities Purchase Agreement”), dated as of January 18, 2011, by and among MabCure, Inc., a Nevada corporation, ("Company"), and Centurion Private Equity, LLC, a Georgia Limited Liability Company ( “Buyer”).
EMPLOYMENT AGREEMENTEmployment Agreement • April 15th, 2011 • Mabcure Inc. • In vitro & in vivo diagnostic substances
MABCURE INC., a corporation organized under the laws of the State of Nevada, having an office at De Schiervellaan 3/B1, 3500 Hasselt, Belgium
AMENDMENT TO INVESTMENT AGREEMENTInvestment Agreement • June 9th, 2011 • Mabcure Inc. • In vitro & in vivo diagnostic substances
THIS AMENDMENT TO INVESTMENT AGREEMENT (the “Amendment”) is entered into as of the 2nd day of June, 2011, by and between MabCure, Inc., a Nevada corporation, ("Company"), and Centurion Private Equity, LLC, a Georgia Limited Liability Company (“Investor”).
AMENDMENT TO THE ESCROW AGREEMENT (the “Amendment”)Escrow Agreement • April 10th, 2009 • Mabcure Inc. • In vitro & in vivo diagnostic substances
THIS AMENDMENT, is made and entered into as of April 2, 2009, by and among MabCure Inc. (the “Company”), Dr. Amnon Gonenne (the “Executive”), and, Clark Wilson LLP (the “Escrow Agent”). (Together the “Parties”, and each individually, a “Party”).
ContractPrivate Placement Subscription Agreement • March 8th, 2010 • Mabcure Inc. • In vitro & in vivo diagnostic substances • Nevada
THIS PRIVATE PLACEMENT SUBSCRIPTION AGREEMENT RELATES TO AN OFFERING OF SECURITIES IN AN OFFSHORE TRANSACTION TO PERSONS WHO ARE NOT U.S. PERSONS (AS DEFINED HEREIN) PURSUANT TO REGULATION S UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "1933 ACT").
INTELLECTUAL PROPERTY TRANSFER AGREEMENTIntellectual Property Transfer Agreement • July 10th, 2008 • Mabcure Inc. • Soap, detergents, cleang preparations, perfumes, cosmetics • New York
INDIGOLEAF ASSOCIATES LTD., a corporation organized under the laws of the British Virgin Islands and having a place of business at c/o Quijano & Associates (BVI) Limited, P.O. Box 3159, Road Town, Tortola, British Virgin Islands
ESCROW AGREEMENTEscrow Agreement • July 10th, 2008 • Mabcure Inc. • Soap, detergents, cleang preparations, perfumes, cosmetics • British Columbia
MABCURE INC., a corporation organized under the laws of Nevada, having an address at 3702 South Virginia Street, Suite G12 – 401, Reno, Nevada 89502, USA
ESCROW AGREEMENTEscrow Agreement • July 10th, 2008 • Mabcure Inc. • Soap, detergents, cleang preparations, perfumes, cosmetics • British Columbia
MABCURE INC., a corporation organized under the laws of Nevada, having an address at 3702 South Virginia Street, Suite G12 – 401, Reno, Nevada 89502, USA
ESCROW AGREEMENTEscrow Agreement • July 10th, 2008 • Mabcure Inc. • Soap, detergents, cleang preparations, perfumes, cosmetics • British Columbia
MABCURE INC., a corporation organized under the laws of Nevada, having an address at 3702 South Virginia Street, Suite G12 – 401, Reno, Nevada 89502, USA
EMPLOYMENT AGREEMENTEmployment Agreement • November 19th, 2008 • Mabcure Inc. • In vitro & in vivo diagnostic substances • Nevada
THIS AGREEMENT is entered into this 7th day of November, 2008. For the purposes of seniority and all rights attendant thereto, this agreement shall be deemed effective as of August 10, 2008 (the "Effective Date"),
LICENSE AGREEMENT (the “Agreement”)License Agreement • November 21st, 2011 • Mabcure Inc. • In vitro & in vivo diagnostic substances • New York
THIS AGREEMENT, is entered into this 10th day of November, 2011, by and between MabCure Inc., a Nevada corporation with a principal place of business at 760 Parkside Avenue, Brooklyn, NY (“MabCure”), and Biotech Investment Corp., a Nevada corporation with a principal place of business at Sharabi Street No. 6, Tel Aviv, 65147 Israel (“NewCo”).
DIRECTOR AGREEMENTDirector Agreement • April 15th, 2011 • Mabcure Inc. • In vitro & in vivo diagnostic substances • New York
THIS DIRECTOR AGREEMENT, (“Agreement”), is entered into this 24th day of September 2010 (the “Effective Date”), by and between MabCure, Inc., a Nevada corporation (“MabCure"), and Gad Berdugo (US Passport No. [_______________]), an individual with an address at ______________________________________________________(the "Director").
ContractSecurities Offering Agreement • March 8th, 2010 • Mabcure Inc. • In vitro & in vivo diagnostic substances • Nevada
THIS AGREEMENT RELATES TO AN OFFERING OF SECURITIES IN AN OFFSHORE TRANSACTION TO PERSONS WHO ARE NOT U.S. PERSONS (AS DEFINED HEREIN) PURSUANT TO REGULATION S UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "1933 ACT").
AMENDMENT TO PRIVATE PLACEMENT SUBSCRIPTION AGREEMENT (“Amendment”)Private Placement Subscription Agreement • September 20th, 2010 • Mabcure Inc. • In vitro & in vivo diagnostic substances
THIS AMENDMENT, effective as of June 27, 2010, is entered into by and between MabCure Inc., a corporation incorporated under the laws of Nevada ("MabCure"), and Paramount Trading Company, a corporation incorporated under the laws of Nevis (the "Investor").
EMPLOYMENT TERMINATION AGREEMENT (the “Agreement”)Employment Termination Agreement • March 24th, 2010 • Mabcure Inc. • In vitro & in vivo diagnostic substances • New York
THIS EMPLOYMENT TERMINATION AGREEMENT, which is effective as of December 31, 2008, is made and entered into by and between MabCure Inc., (“MabCure”), and Dr. Elisha Orr, an individual having an address at 23 Greenhill Road, Leicester LE2 3DN, England (“Executive”).
SMARTEC HOLDINGS INC. 3702 South Virginia Street, Suite #G12 - 401 Reno, Nevada 89502 USAIntellectual Property Sale and Issuance of Shares • July 10th, 2008 • Mabcure Inc. • Soap, detergents, cleang preparations, perfumes, cosmetics • New York
This letter sets out the agreement (this "Agreement") reached among Smartec Holdings Inc. ("Pubco"), a company traded on the NASDAQ Over-the-Counter Market (the "Market"), Indigoleaf Associates Ltd. (the "Vendor") and Dr. Amnon Gonenne (the "Executive"), regarding the transfer and sale by the Vendor of all of its interest and rights to a proprietary technology (the "Technology") for the rapid and efficient generation of monoclonal antibodies (the "Mabs") against desired antigens, such as cancer markers, including, but not limited to, the know-how, secrets, inventions, practices, methods, knowledge and data owned by the Vendor and related thereto, as described on Schedule "A" hereto (the "Intellectual Property Assets") to Pubco, upon the terms and conditions set forth herein.
ContractPrivate Placement Subscription Agreement • June 30th, 2008 • Mabcure Inc. • Soap, detergents, cleang preparations, perfumes, cosmetics • Nevada
THIS PRIVATE PLACEMENT SUBSCRIPTION AGREEMENT RELATES TO AN OFFERING OF SECURITIES IN AN OFFSHORE TRANSACTION TO PERSONS WHO ARE NOT U.S. PERSONS (AS DEFINED HEREIN) PURSUANT TO REGULATION S UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "1933 ACT").
ContractPrivate Placement Subscription Agreement • July 10th, 2008 • Mabcure Inc. • Soap, detergents, cleang preparations, perfumes, cosmetics • Nevada
THIS PRIVATE PLACEMENT SUBSCRIPTION AGREEMENT RELATES TO AN OFFERING OF SECURITIES IN AN OFFSHORE TRANSACTION TO PERSONS WHO ARE NOT U.S. PERSONS (AS DEFINED HEREIN) PURSUANT TO REGULATION S UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "1933 ACT").
DIRECTOR AGREEMENTDirector Agreement • May 13th, 2009 • Mabcure Inc. • In vitro & in vivo diagnostic substances • New York
THIS DIRECTOR AGREEMENT, (“Agreement”), is entered into this 17th day of April 2009 (the “Effective Date”), by and between MabCure, Inc., a Nevada corporation (“MabCure"), and David S. Frank, as Managing Director of MEDx Associates LLC, a New Jersey Limited Liability Company (the "Director").
AMENDMENT TO THE ASSET PURCHASE AGREEMENT (the “Amendment”)Asset Purchase Agreement • April 10th, 2009 • Mabcure Inc. • In vitro & in vivo diagnostic substances
THIS AMENDMENT, is made and entered into as of April 2, 2009, by and among MabCure Inc. (f/k/a Smartec Holdings Inc.), (“Pubco”), Indigoleaf Associates Ltd. (the “Vendor”), and Dr. Amnon Gonenne (the “Executive”). (Together the “Parties”, and each individually, a “Party”).
AMENDMENT TO SECURITIES PURCHASE AGREEMENT AND DEBENTURESecurities Purchase Agreement and Debenture • June 9th, 2011 • Mabcure Inc. • In vitro & in vivo diagnostic substances
THIS AMENDMENT TO SECURITIES PURCHASE AGREEMENT (the “Amendment”) is entered into as of the 2nd day of June, 2011, by and between MabCure, Inc., a Nevada corporation, ("Company"), and Centurion Private Equity, LLC, a Georgia Limited Liability Company (“Buyer”).
MANAGEMENT SERVICES AGREEMENTManagement Services Agreement • March 24th, 2010 • Mabcure Inc. • In vitro & in vivo diagnostic substances
WHEREAS MABCURE is engaged in the business of developing and manufacturing products for cancer detection and therapy;
AMENDMENT TO THE EMPLOYMENT AGREEMENT (the “Amendment”)Employment Agreement • April 10th, 2009 • Mabcure Inc. • In vitro & in vivo diagnostic substances
THIS AMENDMENT, is made and entered into as of April 2, 2009, by and between MabCure Inc., (the “Company”), and Dr. Amnon Gonenne (the “Executive”). (Together the “Parties”, and each individually, a “Party”).
LOAN AGREEMENTLoan Agreement • September 17th, 2009 • Mabcure Inc. • In vitro & in vivo diagnostic substances • Nevada
THIS LOAN AGREEMENT (this “Agreement”) is entered into as of the 2nd day of September 2009, by and between MabCure Inc., a Nevada corporation with an address at De Schiervellaan 3/B1, 3500 Hasselt, Belgium (the “Company”), and Chrysler Enterprises, Ltd., with an address at Main Street, Charlestown, Nevis (the “Lender”).
